Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 28 of 28 publications.
Skip to main content
Weibel D, de Luise C, Elbers R, van den Bor R, Martin I, Cid-Royo A, Plana E, Garcia de Albeniz Martinez X, Weinrib R, Yefimenko N, Poblador-Plou B, Marconi E, Barbieri E, Stona L, Swart KMA, Roy D, Hyeraci G, Bartolini C, Lupattelli A, Villalobos F, Kendrick K, Garg R, Rubino H, Eijkemans R, Sturkenboom M, Arana A. Utilisation patterns of the COVID-19 mRNA vaccine (Comirnaty®) from the VAC4EU active safety surveillance study in five European countries. Poster presented at the 39th ICPE Annual Conference; August 25, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):173-4. doi: 10.1002/pds.5687
Weibel D, Sturkenboom M, Eijkemans R, van den Bor R, Elbers R, Plana E, Garcia de Albeniz X, Weinrib R, Yefimenko N, Bianchini E, Stona L, Poblador-Plou B, Swart-Polinder K, Bartolini C, Hyeraci RG, Roy D, Lupattelli A, Villalobos F, Barbieri E, Garg RK, Rubino H, de Luise C, Arana A. VAC4EU active safety surveillance study of the BNT162b2 COVID-19 vaccine in five European countries: study design and first results. Poster presented at the 2022 ICPE Conference; August 30, 2022. Copenhagen, Denmark. [abstract] Pharmacoepidemiol Drug Saf. 2022 Sep 23; 31(S2):627-8. doi: 10.1002/pds.5518
Marvel J, Goransson O, Clark M, Romano (DeMuro) C, Olayinka-Amao O, Whalley D, Crawford R, Brindicci C, Garg K, Kordy K, Everhard F, Patalano F, Roesler Z, Landles R, Naujoks C, Gutzwiller FS. Interactive tablet application for self-report of asthma symptoms and impacts in young children. Poster presented at the ERS International Congress 2022; September 6, 2022. Barcelona, Spain. [abstract] Eur Respir J. 2022 Sep 4; 60(Suppl 66):2127. doi: 10.1183/13993003.congress-2022.2127
Bego G, Tavi J, Wang Z, Kuznik A, Brignoli L, Mnif T, Wolowacz S, Jia X. Quality of life of caregivers of pediatric patients with atopic dermatitis: a quantitative assessment of utilities from EQ-5D. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2022 Jan; 25(1, Supplement):S101. doi: 10.1016/j.jval.2021.11.480
Lunan M, Hartley L, Pearson I, Doyle S. Targeted literature review of the burden of illness in late-stage Duchenne Muscular Dystrophy (DMD). Poster presented at the Virtual ISPOR Europe 2021; November 3, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
Layton JB, Anderson-Smits C, Ritchey ME, Chavan S, Souayah N. Treatment patterns of US patients with chronic inflammatory demyelinating polyradiculoneuropathy. Poster presented at the 2020 Virtual American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting; October 2020. [abstract] Muscle Nerve. 2020 Oct; p.126.
Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Chavan S, Souayah N. Patient and treatment characteristics of a large US sample of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) initiating Intravenous Immunoglobulin (IVIG) therapy. Poster presented at the 2020 Muscle Study Group (MSG) Annual Virtual Meeting; September 25, 2020. [abstract] RRNMF Neu J. 2020 Sep; 1(4):61.
Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Sehinovych I, Chavan S, Souayah N. Patient and treatment characteristics of a large US sample of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) initiating Intravenous Immunoglobulin (IVIG) therapy. Poster presented at the 2020 Virtual American Academy of Neurology Annual Meeting (Conference cancelled); April 25, 2020. Toronto, Canada. [abstract] Neurology. 2020 Apr 14; 94(15 Supplement):4442.
Houghton K, Dimopoulos M, Lin PL, Guillonneau S, Bury S, Attal M, Richardson PG, Delforge M. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with isatuximab plus pomalidomide and dexamethasone: Icaria-MM study. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):1850. doi: 10.1182/blood-2019-128220
Gilsenan AW, Brainsky A, Colilla S. Applying CIRS-BRAT framework in a regulatory setting: updated benefit risk assessment for fibrinogen concentrate in the setting of complex cardiac surgery. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):964. doi: 10.1002/pds.4864
Sturmer T, Rothman KJ, Ellis AR, Wyss R, Conover M, Lunt M, Glynn RJ. Comparison of propensity score (PS) weighting and trimming strategies to reduce variance and bias of treatment effect estimates: a simulation study. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):53. doi: 10.1002/pds.4629
Ritchey ME, Hunter S, Peterson C, Nguyen L, Thomas S, Harding A, Andrews EB, Rothman KJ, Cainzos-Achirica M, Anthony MS. Cardiovascular safety of phentermine and topiramate in a United States claims database. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):449. doi: 10.1002/pds.4629
Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis. Poster presented at the 5th World Psoriasis & Psoriatic Arthritis Conference 2018; June 27, 2018. Stockholm, Sweden. [abstract] Acta Derm Venereol. 2018 Jun; 98(Suppl 219):14. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.2340/00015555-2978
Raspa M, Sacco P, Bailey DB, Visootsak J, Cabo R. Clinical unmet needs and burden in Fragile X syndrome: results of a targeted literature review. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr 24; 24(4-a):S7. Previously presented at the American Association on Intellectual and Development Disabilities 141st Annual Meeting.
P Sacco, Raspa M, Leahy L, Cabo R. A literature review of the economic burden of Fragile X Syndrome. Poster presented at the 70th AAN Annual Meeting; April 24, 2018. Los Angeles, CA. [abstract] Neurology. 2018 Apr 10; 90(15 Supplement):3.319.
Sacco P, Raspa M, Leahy L, Cabo R. A literature review of the economic burden of Fragile X syndrome. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S7. Previously presented at the 70th AAN Annual Meeting.
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M, Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Garratt C, Weatherall M, Pohjanjousi P, Aantao R, Conti G, Lewis M, Moore N, Perez-Gutthann S. A multinational, drug utilisation study to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice in the EU. Poster presented at the 2015 ESICM's 28th Annual Congress; October 3, 2015. Berlin, Germany. [abstract] Intensive Care Med Exp. 2015 Oct 1; 3(Suppl 1):A322. Previously presented at the 31st ICPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management. doi: 10.1186/2197-425X-3-S1-A322
Perez-Gutthann S, Weatherall M, Garratt C, Pohjanjousi P, Aantaa R, Conti G, Lewis M, Moore N. A multinational, drug utilisation study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Sep; 24(S1):95-6. doi: 10.1002/pds.3838
Johannes CB, Calingaert B, Saltus C, Kaplan S, Grubb E, Kaye JA, Andrews EB. Description of antiparkinsonian drug use in US Medicare claims database: a feasibility assessment. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Aug; 24(S1):85-6.
Wooddell M, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Hogue SL, White MV. Epinephrine administration for cases of anaphylaxis in a US school setting: results from the EpiPen4Schools survey. Poster presented at the 2015 AAAAI Annual Meeting; February 20, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015 Feb; 135(2):AB212.
Hogue SL, Bennett ME, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Wolf RA, Wooddell M, White MV. Occurrence of anaphylaxis by school grade level and staff training: findings from the EpiPen4Schools survey. Poster presented at the 2015 AAAAI Annual Meeting; February 23, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015; 135(2):AB212.
White MV, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Wooddell M, Hogue SL. EpiPen4Schools survey: characteristics of anaphylaxis and common triggers. Poster presented at the 2015 AAAAI Annual Meeting; February 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015; 135:AB212.
Miret M, Perez-Gutthann S, Gutierrez LP, Viglietta V, Musch B, Greenberg S. Evaluation of the long-term safety of Cladribine tablets: design of a prospective 8-year safety registry. Poster presented at the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS); 2009. Dusseldorf, Germany. [abstract] Mult Scler. 2009 Sep 8; 15(Issue Suppl_9):S239. doi: 10.1177/1352458509106963
Acquavella J, Weinhandl E, Bradbury B, Brookhart A, Sturmer T, Rothman KJ. Confounding by indication studying epoetin and mortality. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug 16; 18(Suppl 1):S28.
Perez-Gutthann S, Sturmer T, Platt R, Strom BL, Saddier P, Raine J. How should we plan and communicate interim results of pharmacoepidemiology studies? An ispe public policy forum. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug 16; 18(Suppl 1):S123-4.